SAI Life Sciences posts 23% Q2 revenue growth
SAI Life Sciences reported 23% YoY Q2 FY27 revenue growth and a 28% EBITDA margin as CRO and CDMO operations expanded. The stock gained 3.1% to ₹1,594, while investors track capacity ramp-up and H2 pipeline conversion.
pre-market1 source ↓machine-written, see hownot a recommendation
- SAILIFE close
- ₹1,595
- On the day
- +3.13%
- 52-week high
- ₹1,697
- 52-week low
- ₹783.85
SAI Life Sciences reported 23% year-on-year growth in Q2 FY27 revenue, supported by healthy expansion across its contract research organisation and contract development and manufacturing organisation businesses. The company also reported a 28% EBITDA margin, indicating that growth continued with operating profitability intact. The update was released as integrated pharma partnerships advanced and additional manufacturing capacity moved closer to contributing to revenue.
The stock closed at ₹1,594 on 05 Nov 2026, up 3.1% on the day, according to OI Charts data. Trading volume was 546,517 shares. The shares have gained 6.6% over five sessions and 5.5% over 20 sessions, showing that the earnings update arrived against a positive short-term trend. The stock remains below its 52-week high of ₹1,697 recorded on 09 Sep 2026, but is well above the 52-week low of ₹783.85 recorded on 05 Feb 2026. 📈
Revenue growth 23% and the 28% EBITDA margin are the key operating figures for investors tracking the pharmaceutical outsourcing sector 💊. CRO growth reflects demand for research and development services, while CDMO growth links the company to outsourced drug development and manufacturing programmes. Integrated partnerships can deepen customer relationships and support follow-on work, while new capacity can raise the addressable order pipeline once commercial operations ramp up.
What matters next is the pace at which the expanded capacity is commissioned and absorbed, along with progress across the company’s H2 pipeline. Investors will also watch whether the EBITDA margin remains near the reported level as capacity-related costs rise and new programmes move through development stages. Further disclosures on partnership wins, utilisation, order conversion and segment growth will help establish whether the Q2 performance represents a sustained improvement or a stronger period within the project cycle.
The update followed a period of strong share-price performance, with the stock still 6.1% below its 52-week high based on OI Charts data. The combination of revenue growth, operating margin and capacity ramp-up keeps execution and customer pipeline conversion central to the next market reaction.
Source: TradingView, 05 Nov 2026
Not investment advice. For informational purposes only.